Stem Cells
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Burke, T. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Burke, T. R., Jr

Stem Cells, Vol 12, 1-6, Copyright © 1994 by AlphaMed Press

ORIGINAL ARTICLES

Protein-tyrosine kinases: potential targets for anticancer drug development

TR Burke Jr
Laboratory of Medicinal Chemistry, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.

Protein-tyrosine kinases (PTKs) were originally discovered over a decade ago as the dominant transforming components of certain tumor viruses. Since then these enzymes have become recognized as important intracellular mediators of a variety of mitogenic signaling pathways, including those associated with several growth factor receptors. The strong correlation of aberrant or over-expressed PTKs with a number of proliferative diseases has raised the possibility that PTK inhibitors may afford new approaches toward anticancer therapeutics. To address this possibility, potent and specific PTK inhibitors are needed both as pharmacological probes to study PTK-dependent signaling and as potential antiproliferative agents in their own right. De novo design of PTK inhibitors is hampered by a lack of three dimensional information regarding PTKs or the interaction of inhibitors with the enzymes. Motifs for the design of new inhibitors are therefore frequently derived by modification of structural them identified in natural-product screens. Exemplary of this process is the Laboratory of Medicinal Chemistry's program to develop PTK inhibitors based on pharmacophores present in three natural-product PTK inhibitors: lavendustin A, erbstatin and piceatannol. As summarized in this report, such efforts have led to new inhibitors with increased potency and interkinase selectivity. Whether PTK inhibitors will ultimately prove to be useful as antiproliferative therapeutics remains an open question whose answer will be heavily reliant on a cooperative partnership among natural-product and medicinal chemists, pharmacologists and clinicians.


This article has been cited by other articles:


Home page
 Infect. Immun.Home page
L. R. Schopf, J. L. Bliss, L. M. Lavigne, C. L. Chung, S. F. Wolf, and J. P. Sypek
Interleukin-12 Is Capable of Generating an Antigen-Specific Th1-Type Response in the Presence of an Ongoing Infection-Driven Th2-Type Response
Infect. Immun., May 1, 1999; 67(5): 2166 - 2171.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
STEM CELLS THE ONCOLOGIST CME ALPHAMED PRESS JOURNALS

Copyright © 1994 by AlphaMed Press.